Abstract
The prostate-specific membrane antigen (PSMA) is a great target for prostate cancer in the current. The MH-PC-AB-56, a molecule with PSMA-targeted activity and with an albumin-binding motif, was radiolabeled with indium as a diagnostic agent and with lutetium with a therapeutic agent, respectively. We evaluated the molecule's theranostic application with 111In and 177Lu in NanoSPECT/CT imaging. Methods: The radiolabeled peptide, 111In/177Lu-MH-PC-AB-56, was performed with sodium acetate buffer and heating with 15 min or 30 min at 95℃. The radiochemical purity was analyzed by TLC and HPLC. The PSMA-expressed tumor cell LNCaP was implanted right front leg at BALB/c nude mice. NanoSPECT/CT image was performed at 1 h, 4 h, 24 h, 48 h, 72 h, and 96 h after injection of 111In-MH-PC-AB-56 or 177Lu-MH-PC-AB-56. Results: The radiochemical purity of 111In-MH-PC-AB-56 or 177Lu-MH-PC-AB-56 was 99.09 ± 0.38% and 98.87 ± 0.73% by radio-HPLC analysis, respectively. The in vitro labeling stability of both radiolabeled peptide was 97.0% ± 0.8% and 94.5% ± 2.5% at 4 h in normal saline by radio-HPLC analysis, respectively. The highest uptake of 111In-MH-PC-AB-56 in the tumor appeared at 24 h (43.78 ± 6.55%ID/g), and the uptake in the tumor was a decline after 24 h. During 1 h to 4 h, the kidney and muscle had the highest accumulation of 111In-MH-PC-AB-56 with 37.62 ± 3.69%ID/g to 39.66 ± 7.59%ID/g and 6.58 ± 0.59%ID/g to 6.70 ± 0.45%ID/g, respectively. The highest uptake of 177Lu-MH-PC-AB-56 in the tumor appeared at 24 h (22.08 ± 6.63%ID/g) and retained until 96 h (23.41 ± 5.18%ID/g). During 1 h to 4 h, the kidney had the highest accumulation of 177Lu-MH-PC-AB-56 with 40.35 ± 4.89%ID/g to 42.63 ± 20.14%ID/g. Conclusion: Our results indicated that both 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56 highly accumulated at the tumor lesion, and both 111In-MH-PC-AB-56 and 177Lu-MH-PC-AB-56 were similar distribution in the liver and kidney with positive correlation (r = 0.960 and 0.979) by NanoSPECT/CT imaging.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rahbar et al (2018) Mol Imaging 17:1–9. https://doi.org/10.1177/1536012118776068
Langbein et al (2019) J Nucl Med 60:13S-19S. https://doi.org/10.2967/jnumed.118.220566
Kuo et al (2018) Mol Pharmaceutics 15:5183–5191. https://doi.org/10.1021/acs.molpharmaceut.8b00720
Lo et al (2020) Appl Radiat Isot 161:109126. https://doi.org/10.1016/j.apradiso.2020.109162
Chang et al (2007) Anticancer Res 27:2217–2226
Kuo et al (2020). J Nucl Med. https://doi.org/10.2967/jnumed.120.250738
Umbricht et al (2018) Mol Pharm 15:2297–2306. https://doi.org/10.1021/acs.molpharmaceut.8b00152
Kelly et al (2019) J Nucl Med 65:656–663. https://doi.org/10.2967/jnumed.118.221150
Acknowledgements
We thanked the support from the Ministry of Economic Affairs, ROC with grant number 108-EC-17-A-22-1587.
Funding
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Li, MH. et al. (2022). Evaluation of Radiolabeling PSMA-Targeted Long Circulating Peptide as a Theranostic Agent in Human Prostate Tumor-Bearing Mice. In: Lin, KP., Liu, RS., Yang, BH. (eds) Future Trends and Challenges of Molecular Imaging and AI Innovation. FASMI 2020. Springer Proceedings in Physics, vol 272. Springer, Cham. https://doi.org/10.1007/978-3-030-92786-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-92786-8_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-92785-1
Online ISBN: 978-3-030-92786-8
eBook Packages: Physics and AstronomyPhysics and Astronomy (R0)